APA (7th ed.) Citation

SA, S., G, S., M, G., BA, P., SM, K., SW, N., . . . H, A. (2026). Development and Clinical Validation of OncCNV: A Pipeline for Comprehensive Genome-Wide Analysis of Oncogene Amplifications, Homozygous Deletions, and Biallelic Inactivation of Tumor Suppressor Genes Using the TruSight Oncology 500 Kit. The Journal of molecular diagnostics : JMD, 28(3), 282. https://doi.org/10.1016/j.jmoldx.2025.12.001

Chicago Style (17th ed.) Citation

SA, Smoley, et al. "Development and Clinical Validation of OncCNV: A Pipeline for Comprehensive Genome-Wide Analysis of Oncogene Amplifications, Homozygous Deletions, and Biallelic Inactivation of Tumor Suppressor Genes Using the TruSight Oncology 500 Kit." The Journal of Molecular Diagnostics : JMD 28, no. 3 (2026): 282. https://doi.org/10.1016/j.jmoldx.2025.12.001.

MLA (9th ed.) Citation

SA, Smoley, et al. "Development and Clinical Validation of OncCNV: A Pipeline for Comprehensive Genome-Wide Analysis of Oncogene Amplifications, Homozygous Deletions, and Biallelic Inactivation of Tumor Suppressor Genes Using the TruSight Oncology 500 Kit." The Journal of Molecular Diagnostics : JMD, vol. 28, no. 3, 2026, p. 282, https://doi.org/10.1016/j.jmoldx.2025.12.001.